Using brain stimulation to treat symptoms of depression
Probing the Functional and Behavioral Impact of Precision Circuit Modulation in Neuropsychiatric Diseases
This study is testing whether a new brain stimulation technique can help improve symptoms of depression by targeting specific areas in the brain.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05523817 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of repetitive transcranial magnetic stimulation (rTMS) to target specific brain networks associated with symptoms of Major Depressive Disorder (MDD). By employing advanced imaging techniques, the study aims to understand how stimulating different brain circuits can lead to changes in connectivity and behavior in both depressed and healthy individuals. Participants will undergo rTMS targeting various networks on separate days, allowing researchers to assess the effects on brain function and depressive symptoms. The goal is to develop more personalized and effective treatment strategies for depression.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-65 who are currently experiencing a major depressive episode.
Not a fit: Patients with bipolar disorder, primary psychotic disorders, or significant neurological conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and individualized treatments for patients suffering from depression.
How similar studies have performed: Other studies have shown promise in using rTMS for depression, but this specific approach focusing on network mechanisms is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for healthy participants: * 18-65 years of age * Capacity to provide informed consent form to participate in the study Inclusion Criteria for participants with Major Depressive Disorder (MDD): * 18-65 years of age * Capacity to provide informed consent form to participate in the study * Currently in a major depressive episode. Comorbid anxiety disorders and personality disorders will be allowed provided that MDD is the primary diagnosis. Exclusion Criteria for all participants: * Meeting criteria, in the past or currently, for bipolar affective disorder, hypomania or mania. * Meeting criteria, in the past or currently, for a primary psychotic disorder (e.g., schizophrenia). * Neurological conditions with known structural brain lesions, e.g., intracranial masses, multiple sclerosis. * Any personal history of seizures or a family history of epilepsy in a first-degree relative. * Metal in the body that is ferromagnetic or metallic injury to the eyes. * Implanted pacemakers, medication pumps, vagal stimulators, deep brain stimulators, or ventriculoperitoneal shunts, etc. * Substance abuse or dependence that is current and active within the last six months, as indicated by self-report (e.g., heroin, cocaine, methamphetamines). * Inability to meet the safety criteria for MRI scanning for any other reason. * Severe or unstable medical illness. * Currently pregnant, as assessed with urine pregnancy test in women of childbearing age.
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.